

6 April 2021

**ReNeuron Group plc**  
("ReNeuron" or the "Company")

**Virtual conference attendance and presentations**  
**CEO and CMO to present at Cell & Gene Meeting on the Mediterranean**  
**CEO to present at the Investing in Cures Summit**

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces it will be presenting at two virtual conferences, the virtual Cell & Gene Meeting on the Mediterranean ('Meeting on the Med') conference, which takes place on 6-9 April 2021 and the Investing in Cures Summit, "Latest Advances from Clinical Trials and Industry Partnership", on 12-17 April 2021.

The Meeting on the Med conference is organised by the Alliance for Regenerative Medicine and brings together specialists and companies in the cell and gene therapy community from across Europe. It will be delivered virtually and includes a mix of on demand content that will be released each morning and two live-stream panels each day. Virtual attendees will have access to presentations from over 80 companies, virtual exhibit booths and panel chats.

Richard Beckman, Chief Medical Officer of ReNeuron, will chair a meeting titled "*Gene Therapies for Ophthalmologic Diseases*" as part of the on-demand content available from Tuesday 6 April. The panel will discuss aspects of the eye and ocular disease that make it an attractive target for cell and gene therapy, as well as potential future developments that may occur in the space. CEO, Olav Hellebø, will also be presenting at the event providing an overview and highlighting the Company's technical and clinical achievements over the past 12 months.

For more information and to register for the event, please visit: <https://meetingonthemed.com/>

The Investing in Cures Summit, hosted by the Foundation Fighting Blindness and Retinal Degeneration Fund, is a limited-attendance summit that engages key stakeholders, key opinion leaders, clinical trial investigators, and companies advancing promising therapies. As part of a series of webcasts focused on therapies in development to address retinal degenerations, Olav Hellebø will host a presentation focusing on ReNeuron's technologies and business objectives in the retinal disease space.

No new material will be disclosed at these events and the presentations will be available on the Company website following the events: <http://www.reneuron.com/investors/presentations/>

**Contacts:**

**ReNeuron**

Olav Hellebø, Chief Executive Officer  
Michael Hunt, Chief Financial Officer

[www.reneuron.com/investors](http://www.reneuron.com/investors)

Via Walbrook PR

**Stifel Nicolaus Europe Limited** (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

**Allenby Capital Limited** (Joint Broker)

James Reeve/George Payne (Corporate Finance)  
Tim Sohal (Sales & Corporate Broking)

+44 (0)20 3328 5656

**Walbrook PR** (Media & Investor Relations)

Paul McManus, Alice Woodings

+44 (0)20 7933 8780 or [reneuron@walbrookpr.com](mailto:reneuron@walbrookpr.com)

+44 (0)7980 541 893 / +44 (0)7407 804 654

**About ReNeuron**

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit [www.reneuron.com](http://www.reneuron.com)